Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial.
<h4>Introduction</h4>Current treatments for allergic fungal airway disease are not specific for asthma and are associated with limited efficacy or safety concerns. This Phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial assessed the efficacy and safety of GS...
Main Authors: | Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0281205 |
Similar Items
-
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial
by: Chika Akinseye, et al.
Published: (2023-01-01) -
Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
by: Eleni Pefani, et al.
Published: (2023-04-01) -
Allergic fungal airway diseases: analysis of data in asthma patient register
by: Yana I. Kozlova, et al.
Published: (2023-11-01) -
Proline is increased in allergic asthma and promotes airway remodeling
by: Tingting Xu, et al.
Published: (2023-08-01) -
Dexamethasone attenuates airway inflammation in mouse models with allergic asthma
by: LIU Fen, HU Runfang, MAO Song, XU Min, SHI Wenjing, CHEN Ling
Published: (2023-03-01)